Good Vita / The learning library

LL-37

A peptide appearing in immune-system research discussions.

Educational information only. No medical advice or treatment recommendations.

← Back to the full library

Research compounds Human randomized trial Immune research

Also discussed as: Cathelicidin LL-37

What it is and how it works

LL-37 is a cathelicidin peptide involved in antimicrobial and immune-related biology. Researchers have also studied topical wound-healing formulations. The presence of immune activity does not imply that more activity is always helpful or that an injectable product has the same effects.

Source for the mechanism context →

A closer look at the cited evidence

Human randomized trial

This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.

Study or assessment
Miranda et al., 2023 — LL-37 cream in diabetic foot ulcers
Design
Randomized, double-blind, controlled topical-treatment trial over four weeks.
Who or what was studied
People with mildly infected diabetic foot ulcers.
What was observed
The authors reported improved granulation-related healing measures, but not reductions in the measured inflammatory markers or bacterial colonization.
Limits of interpretation
The result concerns a topical preparation and a defined wound population. It does not establish general immune enhancement or safety of injectable LL-37.
Read the cited study or assessment →

What the evidence means

Immune activity can have multiple consequences; it should not be described as a universal immune boost.

Approval and regulatory context

Not an FDA-approved immune-boosting medicine.

Safety and uncertainty

Safety gaps and nonclinical concerns exist.

What remains uncertain

Formulation, route, wound type, and measured outcome need to remain attached to the claim. Results should not be stretched from one topical study into a general-purpose wellness intervention.

These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.

Sources behind this overview

Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.

Start Your Assessment